Additional treatment options impact first-line treatment of mRCC: No

Additional treatment options impact first-line treatment of mRCC: Yes

Discussion: Additional treatment options impact first-line treatment of mRCC

From clinical trial to clinical practice: Evidence from the real world

What have we learned? Expert perspectives

IEO to have a new Scientific Director at the end of the year when Prof Umberto Veronesi hands over the role to Prof Roberto Orecchia

The evolving treatment landscape for HER2-positive metastatic breast cancer

Navigating current treatment options for HER2-positive MBC: Patient journey 1

ecancermedicalscience editor's choice for September 2014

Benefits of investing in skin cancer prevention

Preventing skin cancer worldwide and the impact of different regulatory and economic priorities

The Euro Melanoma campaign and the importance of communication, education, and understanding of skin cancer